Assurance in clinical trial design

被引:207
|
作者
O'Hagan, A
Stevens, JW
Campbell, MJ
机构
[1] Univ Sheffield, Ctr Bayesian Stat Hlth Econ, Sheffield S3 7RH, S Yorkshire, England
[2] AstraZeneca R&D Charnwood, Loughborough, Leics, England
[3] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England
关键词
assurance; Bayesian analysis; Bayesian clinical trial simulation; binary data; design of experiments; expected power; power; preposterior analysis; prior distribution; sample size;
D O I
10.1002/pst.175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Conventional clinical trial design involves considerations of power, and sample size is typically chosen to achieve a desired power conditional on a specified treatment effect. In practice, there is considerable uncertainty about what the true underlying treatment effect may be, and so power does not give a good indication of the probability that the trial will demonstrate a positive outcome. Assurance is the unconditional probability that the trial will yield a 'positive outcome'. A positive outcome usually means a statistically significant result, according to some standard frequentist significance test. The assurance is then the prior expectation of the power, averaged over the prior distribution for the unknown true treatment effect. We argue that assurance is an important measure of the practical utility of a proposed trial, and indeed that it will often be appropriate to choose the size of the sample (and perhaps other aspects of the design) to achieve a desired assurance, rather than to achieve a desired power conditional on an assumed treatment effect. We extend the theory of assurance to two-sided testing and equivalence trials. We also show that assurance is straightforward to compute in some simple problems of normal, binary and gamma distributed data, and that the method is not restricted to simple conjugate prior distributions for parameters. Several illustrations are given. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:187 / 201
页数:15
相关论文
共 50 条
  • [41] Challenges of clinical trial design for DMD
    Ricotti, Valeria
    Muntoni, Francesco
    Voit, Thomas
    NEUROMUSCULAR DISORDERS, 2015, 25 (12) : 932 - 935
  • [42] The role of sampling in clinical trial design
    Krause, Merton
    Lutz, Wolfgang
    Boehnke, Jan R.
    PSYCHOTHERAPY RESEARCH, 2011, 21 (03) : 243 - 251
  • [43] Clinical trial design for immunomodulatory biologics
    Essayan, DM
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2000, 19 (04): : 255 - 256
  • [44] Considerations in Adapting Clinical Trial Design
    Hung, H. M. James
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2008, 107 (12) : S14 - S18
  • [45] Clinical trial design for cutaneous neurofibromas
    Cannon, Ashley
    Jarnagin, Kurt
    Korf, Bruce
    Widemann, Brigitte C.
    Casey, Denise
    Ko, Hon-Sum
    Blakeley, Jaishri O.
    Verma, Sharad K.
    Pichard, Dominique C.
    NEUROLOGY, 2018, 91 : S31 - S37
  • [46] Innovation in oncology clinical trial design
    Verweij, J.
    Hendriks, H. R.
    Zwierzina, H.
    Hanauske
    Wacheck, V.
    Collignon, O.
    Bruzzi, P.
    Gross, J.
    Riehl, T.
    Bretz, F.
    Dollins
    Radtke, I.
    CANCER TREATMENT REVIEWS, 2019, 74 : 15 - 20
  • [47] Choices in clinical trial design Response
    Karsy, Michael
    Guan, Jian
    Eli, Ilyas
    Brock, Andrea A.
    Menacho, Sarah T.
    Park, Min S.
    JOURNAL OF NEUROSURGERY, 2020, 133 (04) : 1101 - 1102
  • [48] Integrating radiomics into clinical trial design
    Waninger, Jessica J.
    Green, Michael D.
    Cheze Le Rest, Catherine
    Rosen, Benjamin
    El Naqa, Issam
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (04): : 339 - 346
  • [49] Clinical trial design: The nobility of randomization
    Michael, Nelson L.
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (419)
  • [50] STRATIFICATION IN THE DESIGN OF A CLINICAL-TRIAL
    MEIER, P
    CONTROLLED CLINICAL TRIALS, 1981, 1 (04): : 355 - 361